qingfei paidu decoction
prepared from Herba Ephedrae (Ma Huang), Radix Glycyrrhizae (Gan Cao, baked), Semen armeniacae amarum (Ku Xing Ren), Gypsum fibrosum (Sheng Shi Gao), Ramulus Cinmomi (Gui Zhi), Rhizoma Alismatis (Ze Xie), Polyporus umbellatus (Zhu Ling), Atractylodis Macrocephalae Rhizoma (Bai Zhu), Poria (Fu Ling), Stellariae Radix (Chai Hu), Radix Scutellariae (Huang Qin), Pinelliae Rhizoma Praeparatum cum Zingibere (Jiang Ban Xia), Rhizoma Zingiberis Recens (Sheng Jiang), Radix asteris (Zi Wan), Flos farfarae (Kuan Dong Hua), Rhizoma Belamcandae (She Gan), Herba Asari (Xi Xin), Rhizoma Dioscoreae (Shan Yao), Fructus Aurantii Immaturus (Zhi Shi), Pericarpium Citri Reticulatae (Chen Pi), and Pogostemon Cablin (Blanco) Benth (Guang Huo Xiang)
Networked: 39
relevant articles (14 outcomes,
6 trials/studies)
Relationship Network
Bio-Agent Context: Research Results
Experts
1. | Ma, Yan:
3 articles
(07/2022 - 11/2020)
|
2. | Tong, Lin:
3 articles
(07/2022 - 11/2020)
|
3. | Chen, Renbo:
2 articles
(07/2022 - 11/2020)
|
4. | Fan, Yipin:
2 articles
(07/2022 - 11/2020)
|
5. | Ge, Youwen:
2 articles
(07/2022 - 11/2020)
|
6. | Liang, Ning:
2 articles
(07/2022 - 11/2020)
|
7. | Liu, Sihong:
2 articles
(07/2022 - 11/2020)
|
8. | Shi, Nannan:
2 articles
(07/2022 - 11/2020)
|
9. | Wang, Wei:
2 articles
(07/2022 - 11/2020)
|
10. | Wang, Yanping:
2 articles
(07/2022 - 11/2020)
|
Related Diseases
1. | COVID-19
|
2. | Pneumonia (Pneumonitis)
|
3. | Virus Diseases (Viral Diseases)
|
4. | Asymptomatic Infections
01/01/2020
- " They covered topics of chemoprophylaxis (including agents and Traditional Chinese Medicine (TCM) agents), diagnosis (including clinical manifestations, reverse transcription-polymerase chain reaction (RT-PCR), respiratory tract specimens, IgM and IgG antibody tests, chest computed tomography, chest x-ray, and CT features of asymptomatic infections), treatments (including lopinavir-ritonavir, umifenovir, favipiravir, interferon, remdesivir, combination of antiviral drugs, hydroxychloroquine/chloroquine, interleukin-6 inhibitors, interleukin-1 inhibitors, glucocorticoid, qingfei paidu decoction, lianhua qingwen granules/capsules, convalescent plasma, lung transplantation, invasive or noninvasive ventilation, and extracorporeal membrane oxygenation (ECMO)), and discharge management (including discharge criteria and management plan in patients whose RT-PCR retesting shows SARS-CoV-2 positive after discharge). "
|
5. | Lung Injury
|
|
Related Drugs and Biologics
Related Therapies and Procedures